Holen Sie sich die Stockscreener-App
33.10
1.07%
0.35
Handel nachbörslich:
33.10
Schlusskurs vom Vortag:
$32.75
Offen:
$32.62
24-Stunden-Volumen:
9.01M
Relative Volume:
2.03
Marktkapitalisierung:
$14.08B
Einnahmen:
$2.27B
Nettoeinkommen (Verlust:
$1.15B
KGV:
12.98
EPS:
2.55
Netto-Cashflow:
$2.80B
1W Leistung:
+1.91%
1M Leistung:
+7.29%
6M Leistung:
+26.29%
1J Leistung:
+18.26%
1-Tages-Spanne:
$32.37
$34.11
1-Wochen-Bereich:
$31.97
$34.11
52-Wochen-Spanne:
$24.05
$34.20
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
33.10 | 14.08B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma’s Earnings Call: Growth and Optimism - TipRanks
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Earnings call transcript: Royalty Pharma Q1 2025 misses EPS estimates - Investing.com
Royalty Pharma plc SEC 10-Q Report - TradingView
Royalty Pharma earnings missed by $0.66, revenue fell short of estimates - Investing.com UK
Royalty Pharma Q1 2025 slides: double-digit growth drives raised guidance - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates - Yahoo Finance
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Royalty Pharma Reports First Quarter 2025 Results - TradingView
Cutter Capital Management LP Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Reports 17% Growth in Portfolio Receipts to $839 Million and Raises 2025 Financial Guidance - Nasdaq
AQR Capital Management LLC Boosts Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
MML Investors Services LLC Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Price T Rowe Associates Inc. MD Cuts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Northern Trust Corp Acquires 376,619 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Dimensional Fund Advisors LP Boosts Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Caisse DE Depot ET Placement DU Quebec Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
ArrowMark Colorado Holdings LLC Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Projected to Post Earnings on Thursday - MarketBeat
PDT Partners LLC Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Hsbc Holdings PLC Sells 30,304 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics - Nasdaq
AlTi Global Inc. Buys Shares of 387,567 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Holdings Boosted by Regal Partners Ltd - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Tudor Investment Corp ET AL - MarketBeat
First Trust Advisors LP Decreases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Wells Fargo & Company MN Buys 15,790 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Moody’s upgrades Royalty Pharma’s rating, maintains stable outlook By Investing.com - Investing.com Nigeria
Moody’s upgrades Royalty Pharma’s rating, maintains stable outlook - Investing.com Australia
Walleye Capital LLC Buys Shares of 25,124 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Uniplan Investment Counsel Inc. Buys New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Dark Forest Capital Management LP - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by GMT Capital Corp - MarketBeat
Barclays PLC Acquires 54,421 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Declares $0.22 Quarterly Dividend - MarketBeat
Brokerages Set Royalty Pharma plc (NASDAQ:RPRX) Price Target at $42.50 - MarketBeat
Cerity Partners LLC Sells 15,537 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Canada Pension Plan Investment Board Buys 39,070 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Guggenheim Capital LLC Sells 82,768 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.88%
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):